RTP Mobile Logo
Dermatologic Oncology Update, Issue 1, 2013
Released July 2013

Featuring interviews with Drs Keith T Flaherty, Rene Gonzalez, Anna C Pavlick and Jeffery A Sosman. (Text and Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY
    Taken together, melanoma and nonmelanoma skin cancer — basal cell carcinoma (BCC) and cutaneous squamous cell cancer (SCC) — likely represent the most prevalent form of human cancer. Fortunately, the vast majority of skin cancers present as minimally invasive BCC and SCC and, as such, are highly curable with local treatment alone. However, in rare instances these characteristically indolent lesions progress and necessitate systemic intervention with the support of limited randomized clinical evidence. In contrast, cancerous melanoma is the most aggressive form of skin cancer with a predilection toward distant metastases, even when identified in the early stages of the disease. Thus melanoma and nonmelanoma skin cancer are distinct entities, each posing unique challenges to the oncology community. Featuring information on the latest research developments along with expert perspectives, this CME activity is designed to assist medical oncologists and hematology-oncology fellows with the formulation of up-to-date clinical management strategies.

    LEARNING OBJECTIVES

    • Develop a treatment algorithm for BRAF V600 mutation-positive and wild-type advanced melanoma.
    • Counsel patients regarding the risk of BRAF inhibitor-associated secondary nonmelanoma skin cancers and other cutaneous and noncutaneous adverse events, and implement appropriate surveillance and management strategies.
    • Recognize immune-related adverse events associated with anti-CTLA-4 antibody therapy with ipilimumab, and offer supportive management strategies to minimize and/or manage these side effects.
    • Evaluate the potential clinical and research implications of recent Phase III trial results evaluating the combination 
of MEK and BRAF inhibitors in the treatment of melanoma.
    • Appraise the rationale for and clinical data with investigational anti-PD-1 immunotherapy for advanced solid tumors.
    • Rationally incorporate established and novel cytotoxic agents into the treatment algorithm for advanced melanoma.
    • Identify patients with locally advanced or metastatic BCC for whom hedgehog inhibitor therapy may be an 
appropriate treatment option.
    • Counsel appropriately selected patients about participation in ongoing clinical trials.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue


    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue


    HOW TO USE THIS CME ACTIVITY
    This CME activity contains both audio and print components. The participant should listen to the audio MP3s and read the text portion. The text portion of this activity contains edited comments, clinical trial schemas, graphics and references that supplement the audio MP3s, as well as links to relevant full-text articles, abstracts, trial information and other web resources.

    CME credit is no longer available for this issue


    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr FlahertyAdvisory Committee: Boehringer Ingelheim Pharmaceuticals Inc, Eisai Inc, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Sanofi; Consulting Agreements: Genentech BioOncology, GlaxoSmithKline, Momenta Pharmaceuticals Inc, Otsuka Pharmaceutical Co Ltd, Roche Laboratories Inc; Contracted Research: Novartis Pharmaceuticals Corporation, Sanofi. Dr GonzalezAdvisory Committee: Bristol-Myers Squibb Company, Genentech BioOncology, Roche Laboratories Inc; Consulting Agreements: Genentech BioOncology, Roche Laboratories Inc; Contracted Research: Bristol-Myers Squibb Company, Celgene Corporation, Eisai Inc, Genentech BioOncology, GlaxoSmithKline, Merck, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc; Data Monitoring Committee: GlaxoSmithKline. Dr PavlickPaid Research: Bristol-Myers Squibb Company, Eisai Inc, Genentech BioOncology, GlaxoSmithKline, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Pfizer Inc; Speakers Bureau: Bristol-Myers Squibb Company, Genentech BioOncology. Dr SosmanAdvisory Committee: Genentech BioOncology, GlaxoSmithKline, Millennium: The Takeda Oncology Company.

    EDITOR
    Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly USA LLC, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Celgene Corporation, Genentech BioOncology and Prometheus Laboratories Inc.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio
    A high-speed Internet connection

    Last review date: July 2013
    Expiration date: July 2014

Acknowledge and close

Listen to audio:
Dermatologic Oncology Update, Issue 1, 2013
Released July 2013

Featuring interviews with Drs Keith T Flaherty, Rene Gonzalez, Anna C Pavlick and Jeffery A Sosman. (Text and Audio Content)

Read print: